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A plethora of active compounds found in herbal medicines can serve as substrate
for enzymes involved in the metabolism of xenobiotics. When a medicinal plant is
co-administered with a conventional drug and little or no information is known about the
pharmacokinetics of the plant metabolites, there is an increased risk of potential herb-drug
interactions. Moreover, genetic polymorphisms in a population may act to predispose
individuals to adverse reactions. The use of herbal medicines is rapidly increasing in many
countries, particularly Brazil where the vast biodiversity is a potential source of new and
more affordable treatments for numerous conditions. Accordingly, the Brazilian Unified
Public Health System (SUS) produced a list of 71 plant species of interest, which could be
made available to the population in the near future. Physicians at SUS prescribe a number
of essential drugs and should herbal medicines be added to this system the chance of
herb-drug interactions further increases. A review of the effects of these medicinal plants
on Phase 1 and Phase 2 metabolic mechanisms and the transporter P-glycoprotein was
conducted. The results have shown that approximately half of these medicinal plants
lack any pharmacokinetic data. Moreover, most of the studies carried out are in vitro.
Only a few reports on herb-drug interactions with essential drugs prescribed by SUS
were found, suggesting that very little attention is being given to the safety of herbal
medicines. Here we have taken this information to discuss the potential interactions
between herbal medicines and essential drugs prescribed to Brazilian patients whilst
taking into account the most common polymorphisms present in the Brazilian population.
A number of theoretical interactions are pinpointed but more pharmacokinetic studies and
pharmacovigilance data are needed to ascertain their clinical significance.
Keywords: herb-drug interactions, cytochrome P450, glutathione, glucuronidation, P-glycoprotein, polymorphism,
Brazil, pharmacovigilance
INTRODUCTION
Consumption of herbal medicines has been increasing world-
wide over the past few years. In developed countries, such as the
United Kingdom, around 50% of the population have used herbal
medicines at least once in their life and, surprisingly, almost 100%
of HIV patients in the country have admitted to using herbal
medicines (Caminal Homar, 2005). In developing countries, the
World Health Organization (WHO) estimates that 65–80% of
the population relies on herbal medicines as a primary source
of treatment (Rahman and Singhal, 2002). These statistics are
in line with Brazil, where 66% of the population have no access
to commercial medicines (Trojan-Rodrigues et al., 2012). Even
when access is granted, popular use of herbal medicines is often
due to poor medical and pharmaceutical assistance and the high
cost of treatment with conventional drugs (Silveira et al., 2008).
Brazilians are also becoming more interested in “safe” and “natu-
ral” treatments aimed to promote healthier living. A consequence
of this increased use of phytotherapy has been a higher num-
ber of case reports on adverse reactions caused by uncontrolled
consumption of herbal medicines (Silveira et al., 2008).
The Brazilian Health Surveillance Agency (ANVISA) is in
charge of the regulation of herbal medicines in the country and
since its creation in 1999, many advances have beenmade in order
to control and ensure their efficacy and safety (Balbino and Dias,
2010). To guarantee that the phytomedicinal candidate is safe for
consumption by humans, the Agency established a requirement
that at least 20 years of prior traditional use must be attested. In
the absence of this evidence the efficacy and safety of the candi-
date needs to be demonstrated by a point based system according
to literature data, preclinical and clinical tests or indication that
the herb is already included in the List of Simplified Registration
of Herbal Medicines (ANVISA, 2010). Although these regula-
tions are relevant to improve the safety and efficacy of herbal
medicines, pharmacokinetic studies on the plants are not yet a
regulatory requirement. As a consequence, there is a scarcity of
this kind of data which is regarded as an oversight in terms of
safety (Ribeiro et al., 2005).
The SUS is one of the biggest public health systems in the
world, responsible for approximately 140 million Brazilian cit-
izens (Mendes, 2013). In order to establish which medicines
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should be provided by SUS, the Brazilian Health Ministry pro-
duced a list of essential drugs according to the International
Classification of Diseases (ICD) and epidemiological studies con-
ducted nationwide (Saúde, 2010; SUS, 2010). Several herbal
medicines are already part of this list, such as Cynara scolymus L.,
Schinus terebinthifolius, and Rhamnus purshiana. However, due to
the extensive number of plant species possessing pharmacological
activity used in Brazil, the Health Ministry determined that more
herbal medicines should be provided by the System to the popula-
tion, as part of one of the aims of the National Policy of Integrative
and Complementary Practices (PNPIC). Consequently, the list of
medicinal plants of interest of SUS (RENISUS) was published
in 2008 and, from this point on, efforts have been concentrated
on elucidating the efficacy and safety of the 71 plant species
present on the list (Saúde, 2009; SUS, 2009; cf. Feijó et al.,
2012).
The pharmacokinetic profile of pharmaceutical drugs is essen-
tial to determine whether or not they will interact with other ther-
apeutic interventions (Ionescu and Caira, 2005). Polymorphism
studies are also relevant because they may impact the capacity
to metabolize xenobiotics, thus leading to adverse drug reactions
(ADRs) within certain ethnicities (Suarez-Kurtz, 2005). However,
pharmacokinetic studies on medicinal plants are very difficult
to carry out because of their chemical complexity (Simões and
Mariot, 2003). As a result, there is very little data for numer-
ous native and exotic plants that are traditionally used in Brazil
(He et al., 2010). The in vitro pharmacokinetic profile of a few
herbal medicines can be found in the literature and, although
these data are important, they are seldom used for the prediction
of potential herb-drug interactions. Thus, the aim of this article is
to provide an overview and critical evaluation of the pharmacoki-
netic data of medicinal plants to be used in the Brazilian health
system. By discussing the potential herb-drug interactions with
essential drugs upon Phase 1 and Phase 2 metabolic mechanisms
and P-Glycoprotein activity, we intend to prompt race awareness
on the safety of herbal medicines in Brazil.
METHODOLOGY
A literature search was conducted using the Library of Medicine’s
PubMed database between May and June 2013. Included stud-
ies consisted of the reported effects of the medicinal plants of
RENISUS list on the main liver metabolic enzymes, which are
involved in Phase 1 (functionalization reactions mediated by
cytochrome P450) and Phase 2 (glutathione conjugation, glu-
curonidation, sulfation, methylation and acetylation)metabolism
and also the assessment of their effects on P-glycoprotein activ-
ity. The following combinations of keywords were used: “Plant
name AND, 1A2, 3A4, 3A5, 3A7, 2C9, 2C19, 2D6, 2E1,” “Plant
name AND glutathione,” or “Plant name AND gsh,” “Plant name
AND glucuronidation” or “Plant name AND ugt,” “Plant name
AND sulfation,” “Plant name AND sulfate conjugation,” “Plant
name AND sulfotransferase,” “Plant name AND methylation,”
“Plant name ANDmethyltransferase,” “Plant name AND acetyla-
tion,” “Plant name AND n-acetyltransferase,” “Plant name AND
P-glycoprotein” or “Plant name AND Pgp.” EndNote web was
the citation tool used to manage and organize all the references
collected.
It is important to note that the list of Brazilian medicinal
plants of interest of SUS encompass native and exotic adapted
plant species and that we are aware of the chemical variabil-
ity of the materials, which eventually may be harmonized by
pharmacopoeial monographs of their respective countries.
PHASE 1 METABOLISM AND THE HUMAN LIVER
CYTOCHROMES P450
Xenobiotic metabolism is normally divided into two phases:
Phase 1 (functionalization reactions) and Phase 2 (conjuga-
tive reactions). Phase 1 reactions prepare the drug for Phase 2
metabolism by adding polar functional groups to the xenobiotic
(Ionescu and Caira, 2005).
Human drug-metabolizing enzymes are present ubiquitously
in the body. Over 50 human cytochromes P450 have already
been isolated; the major ones found in the liver include CYP1A2,
CYP2E1, CYP2C9/19, CYP2D6, and CYP3A4/5/7 (Figure 1)
(Gibson and Skett, 2001). The CYP 1, 2, and 3 are the most abun-
dant families of CYP metabolizing enzymes and the CYP1A2,
CYP2C, and CYP3A4 isoforms account for about 30% of the
metabolism of the majority of drugs (Atkinson, 2012).
The cytochrome P450 monooxygenase enzymes are located in
the smooth endoplasmic reticulum of the liver and other extra
hepatic tissues. Numerous drugs are metabolized by cytochrome
P450 enzymes through oxidation reactions such as aromatic
and aliphatic hydroxylation, epoxidation, N-dealkylation, O-
dealkilation, S-dealkylation, oxidative deamination,N-oxidation,
S-oxidation, phosphothionate oxidation, dehalogenation, and
alcohol oxidation. Reduction, hydrolysis and hydration are other
examples of Phase 1 reactions catalyzed by the cytochrome P450
(Ionescu and Caira, 2005).
Similar to conventional drugs, herbal medicines also undergo
Phase 1 and Phase 2 metabolism in order to be excreted from
the body. If a herbal medicine is concomitantly used with a con-
ventional drug, for example, the first may inhibit or induce the
activity and expression of a specific cytochrome that could be the
same one responsible for the metabolism of the latter, leading to
herb-drug interactions (Hu et al., 2005).
FIGURE 1 | The main liver cytochrome P450 isoenzymes and
approximate percentage of expression.
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GENETIC POLYMORPHISM
Responses to drug consumption differ among individuals due to
the variability of CYP content. A predefined dosage of a medicine
might be enough to exert a pharmacological effect in one patient
but it may be necessary to be adjusted for another patient to
achieve the same effect. This can be explained by genetic polymor-
phisms within CYPs that can affect the metabolism of xenobiotics
in general, leading to changes in drug response and increased risk
of ADRs (Zhou et al., 2009). For example, the biodisponibility
of Omeprazole, which is a drug that is metabolized by CYP3A4
and CYP 2C19, demonstrated to be slower in Mexicans when
compared with Caucasians but faster than that of Asians. The eth-
nic mixture of the Mexican population is a plausible explanation
for differences in metabolic response compared to other ethnic
groups (Gonzalez et al., 2003).
The genomic diversity of the Brazilian population is a result
of the genetic admixture of three groups: Europeans, Africans
and Amerindians. Due to this very distinctive miscegenation,
polymorphisms in cytochromes levels are undoubtedly present
among Brazilians (Suarez-Kurtz, 2005). The Brazilian National
Pharmacogenetics/Pharmacogenomics Network (REFARGEN)
carried out studies in four regions of Brazil in order to map
the genetic diversity of the population (Suarez-Kurtz, 2004). The
study divided the population into three distinct races: white,
brown and black. The results obtained from REFARGEN showed
that numerous polymorphisms were found on cytochromes 2C9,
2C19, 2D6, and 3A5.
Taking all these points into consideration, from the data gath-
ered in our literature review we will summarize some potentially
clinically relevant pharmacokinetic effects of herbal medicines
in metabolic enzymes responsible for Phase 1 and Phase 2
metabolisms and P-glycoprotein activity. Also, the presence of
polymorphisms among the Brazilian population and its implica-
tion in the metabolism were assessed. Some interactions between
essential drugs and herbal medicines in Brazil found in the litera-
ture will be shown, which will eventually need to be put to test in
the laboratory or followed up epidemiologically.
EFFECTS OF HERBAL MEDICINES IN PHASE 1 ENZYMES AND
HERB-DRUG INTERACTIONS
CYP1A2
This cytochrome isoform is mainly found in the liver (15%)
and it metabolizes almost 20% of the current therapeutic arsenal
(Wang and Zhou, 2009). Amid the 71 plant species, nine of them
were found to interfere with the activity of CYP1A2 (Table 1).
Examples of essential drugs, which are substrates for the CYP1A2,
include the highly popular painkiller Acetaminophen, the beta-
blocker Propranolol, the antidepressant Clomipramine and the
anticoagulant Warfarin.
Acetaminophen (Paracetamol) is bioactivated via CYP1A2,
CYP3A4, and CYP2E1, resulting in the production of the toxic
compound N-acetyl–p–benzoquinone (NAPQI). In normal con-
ditions, the drug is detoxified by conjugation with glutathione.
However, in cases of overdose, this metabolic route becomes sat-
urated, increasing the bioactivation of NAPQI and its binding
to other molecules, such as proteins, resulting in damages to the
liver due to cell death (Lee et al., 2001). Intake of Acetaminophen
Table 1 | Medicinal plant species listed in RENISUS with reported
effects of on CYP1A2.
Plant
species/Family
Effects on CYP1A2 References
Allium sativum
(Aliaceae)
+ Le Bon et al., 2003
Curcuma longa
(Zingiberaceae)
+ Thapliyal et al., 2002
Eucalyptus
globulus
(Myrtaceae)
− Unger and Frank,
2004
Glycine max
(Leguminosae)
− Shon and Nam, 2004
Harpagophytum
procumbens
(Pedaliaceae)
NE, − Unger and Frank,
2004; Modarai et al.,
2011
Mentha piperita
(Lamiaceae)
− Unger and Frank,
2004
Phyllanthus
amarus
(Euphorciaceae)
− Hari Kumar and
Kuttan, 2006
Punica granatum
(Lythraceae)
− Faria et al., 2007a
Trifolium
pratense
(Fabaceae)
− Unger and Frank,
2004
+, Enzyme induction; −, Enzyme inhibition; NE, No Effect.
with Allium sativum and Curcuma longa could theoretically
increase the toxicity of the drug due to accumulation of NAPQI
caused by induction of CYP1A2. On the other hand, consump-
tion of Acetaminophen with medicinal plants such as Phyllantus
amarus, Mormodica charantia, Eucalyptus globulus, Glycine max,
Harpagophytum procumbens, Mentha piperita, Trifolium pratense
and Punica granatum based remedies may decrease levels of this
toxic metabolite because of CYP1A2 enzyme inhibition.
Although it appears that garlic consumption can put the
integrity of hepatocytes at risk, a study conducted by Gwilt
et al. (1994) proved that the garlic extract administration has
little effect on the metabolism of Acetaminophen. In this study
16 male nonsmokers took 10ml of garlic extract daily for 3
months. Acetaminophen was administered at five different time
points: before garlic treatment, at the end of the first, second,
and third month of garlic extract consumption and 1 month after
interruption of garlic treatment. The results demonstrated that
garlic extract does not interfere with the oxidative pathway of
Acetaminophen and therefore it does not represent a potential
risk for hepatocytes.
The beta-blocker Propranolol and the tricyclic antidepressant
Clomipramine are essential drugs extensively prescribed in Brazil.
The biotransformation of Propranolol and Clomipramine starts
with the N-dealkilation, governed by S-mephenytoin (CYP1A2)
for the former and the N-demethylation of the side chain
of the molecule of the latter to form the active metabolite
desmethylclomipramine (DCIP) (Nielsen et al., 1996). Therefore,
plant species that inhibit CYP1A2 must be avoided during the
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treatment period with these drugs. This is, however, theoretical
and in this case no reports have so far been found in the literature.
The anticoagulant Warfarin is indicated for the treatment of
venous thrombosis and pulmonary embolism. The pharmacoki-
netics of this drug can easily be altered by CYP1A2 inhibitors.
A rare case of interaction of warfarin with garlic supplements
has been reported, leading to excessive bleeding (Baxter and
Stockley, 2008). Other cases of herb-drug interactions were
detected after co-administration of Curcuma longa, Glycine max,
Harpagophytum procumbens, Punica granatum, and Trifolium
pratense with Warfarin, resulting in pharmacokinetic alterations
(Heck et al., 2000; Cambria-Kiely, 2002; Ramsay et al., 2005;
Komperda, 2009; Liu et al., 2013).
CYP1A2 is considered to be highly inducible and polymor-
phic. Two polymorphisms were found to be common in South
Brazilians: the CYP1A2∗1F and ∗1K alleles. They cause higher
and decreased enzyme expression, respectively (Kohlrausch et al.,
2014). Their high frequency in Southern Brazilians suggests that
chances of ADRs may be increased within this group.
CYP2C9
The CYP2C9 is the major CYP2C isoform found in the human
liver and typical substrates are molecules that contain an anionic
site and a hydrophobic site (Mo et al., 2009). This CYP
enzyme metabolizes approximately 15% of clinical drugs, includ-
ing the nonsteroidal anti-inflammatory (NSAID) Ibuprofen,
the antihypertensive Losartan, the antidepressant Fluoxetine,
the antiepileptic Phenytoin and the anti-hypercholesterolemic
Fluvastatin (Baxter and Stockley, 2008; Berka et al., 2011). Certain
endogenous bioactive substances such as steroids, melatonin,
retinoids and arachidonic acid are also metabolized by this CYP
family (Mo et al., 2009).
Ibuprofen is a commonmedication prescribed by SUS to com-
bat pain and inflammation. The drug is also included in theWHO
Model List of Essential Medicines as a drug for pain and pal-
liative care and as an antimigraine medicine (Medicines, 2012;
WHO, 2012, 2013). As mentioned above, Ibuprofen is mostly
metabolized by CYP2C9 leading to the formation of the active
metabolite (S)-ibuprofen. Herbal species that are substrates for
CYP2C9 (Table 2), may inhibit the formation of (S)-ibuprofen,
potentially leading to therapeutic failure (Mo et al., 2009).
The active metabolites E-3174, norfluoetine, 4′-HPPH and 6-
hydroxy fluvastatin, are formed through the action of CYP2C9
on the essential drugs Losartan, Fluoxetine, Phenytoin and
Fluvastatine, respectively (von Moltke et al., 1997; Scripture and
Pieper, 2001; Joy et al., 2009). Concomitant consumption of those
drugs along with any of the plant species listed on Table 2 could
impact on the formation of these substances.
The CYP2C9∗2 and ∗11 alleles were found in higher fre-
quency in white Brazilians, whereas CYP2C9*3 was mostly
found in browns and CYP2C9∗5 in the black population. These
polymorphisms decrease the enzyme activity in vitro (Zhou
et al., 2009) therefore consumption of medicinal plants such
as garlic, eucalyptus, devil’s claw, mentha, pomegranate, red
clover and ginger may further inhibit their function or expres-
sion, potentially causing herb-drug interactions in these ethnic
groups.
Table 2 | Medicinal plant species listed in RENISUS with reported
effects of on CYP2C9.
Plant
species/Family
Effects on CYP2C9 References
Allium sativum
(Aliaceae)
−, + Foster et al., 2001;
Ho et al., 2010
Eucalyptus globulus
(Myrtaceae)
− Unger and Frank,
2004
Harpagophytum
procumbens
(Pedaliaceae)
NE, − Modarai et al., 2011
Mentha piperita
(Lamiaceae)
− Unger and Frank,
2004
Punica granatum
(Lythraceae)
− Hanley et al., 2012
Trifolium pratense
(Fabaceae)
− Unger and Frank,
2004
Zingiber officinale
(Zingiberaceae)
− Kimura et al., 2010
+, Enzyme induction; −, Enzyme inhibition; NE, No Effect.
CYP2C19
Cytochrome P450 2C19 is not only involved in the metabolism
of a range of drugs but it also plays a crucial role in the detox-
ification and inactivation of some potential carcinogens (Wang
et al., 2013). CYP2C19 is responsible for the metabolism of
about 10% of prescribed drugs, including a number of essential
ones such as the proton pump inhibitor Omeprazole, the tri-
cyclic antidepressant Amitriptyline, the selective serotonin reup-
take inhibitor Fluoxetine, the benzodiazepine Diazepam and the
barbiturate Phenobarbital (Zhou et al., 2009). About 24 vari-
ants of CYP2C19 are known of which three of them were
found by REFARGEN in the Brazilian population: CYP2C19∗2,
CYP2C19∗3, and CYP2C19∗17. The alleles ∗2 and ∗3 appear not
to effect the enzyme activity, whereas CYP2C19∗17 increases in
vitro activity and is the most prevalent.
The plant species Allium sativum, Eucalyptus globulus,Mentha
piperita, and Trifolium pratense were found to be CYP2C19
inhibitors (Table 3). Due to the extensive use of these herbal
medicines that are metabolized by CYP2C19, herb-drug inter-
actions at this level could be very frequent but so far no clinical
report has been found.
CYP2D6
Although the level of expression of the cytochrome P450 2D6 in
the human liver is only about 5%, it metabolizes about 25% of all
medications in human liver (Ionescu and Caira, 2005). Essential
drugs such as the beta-blockers Propafenone and Timolol, the
antidepressant Amitriptyline, the antipsychotic Haloperidol and
Risperidone, and the antihistamine Chlorphenamine are metab-
olized by this isoform (Zhou et al., 2009). Polymorphisms on
CYP2D6 are the most studied among the CYPs. To date, 72 vari-
ants of this isoform were found in humans and 16 were detected
in Brazilians according to REGARGEN: CYP2D6∗1, ∗2, ∗3, ∗4, ∗5,
∗9, ∗10, ∗17, ∗29, ∗34, ∗35, ∗39, ∗41, ∗1XN, ∗2XN, and ∗4XN. An
increase in enzyme activity was found on the alleles ∗1XN and
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Table 3 | Medicinal plant species listed in RENISUS with reported
effects of on CYP2C19.
Plant
species/Family
Effects on CYP2C19 References
Allium sativum
(Aliaceae)
− Foster et al., 2001
Eucalyptus globulus
(Myrtaceae)
− Unger and Frank,
2004
Harpagophytum
procumbens
(Pedaliaceae)
NE Modarai et al., 2011
Mentha piperita
(Lamiaceae)
− Unger and Frank,
2004
Trifolium pratense
(Fabaceae)
− Unger and Frank,
2004
+, Enzyme induction; −, Enzyme inhibition; NE, No Effect.
∗2XN, whereas a decrease of activity was found on ∗9, ∗10, ∗17,
∗29, and ∗41.
The popular medicinal plants Eucalyptus globulus,
Harpagophytum procumbens, Mentha piperita, Phylanthus
amarus, Punica granatum, and Trifolium pratense are shown to
inhibit the activity of CYP2D6 in liver cells (Table 4). Brazilians
who take these herbal drugs may have increased chances of ADRs,
although no clinical reports were found in the literature.
CYP2E1
The cytochrome P450 2E1 represents 10% of the total CYPs
expressed in the human liver and it is well known for its involve-
ment in the metabolism of ethanol to acetaldehyde, and accord-
ingly it is rapidly induced after ethanol ingestion (Anzenbacher
and Anzenbacherova, 2001). This cytochrome isoform is respon-
sible for the activation of some carcinogens, procarcinogens
and toxicants and it metabolizes mainly low-molecular-weight
compounds. CYP2E1 also has the ability to produce reactive
intermediates, leading to the formation of free radicals such as
superoxide, hydroxyl radical, and lipid peroxides (Neafsey et al.,
2009). Polymorphisms on CYP2E1 in the Brazilian population
have not yet been mapped by REFARGEN, but one case of herb-
drug interaction involving this enzyme has been reported (Hau
et al., 2009). According to our literature search, Allium sativum,
Momordica chrantia, Phyllanthus amarus, Phyllanthus urinaria,
and Punica granatum decrease levels and activity of CYP2E1 in
the liver (Table 5). As Acetaminophen is also metabolized by
CYP2E1, NAPQI can be also formed at this metabolic route.
Therefore, consumption of these medicinal plants could reduce
the formation of the toxic metabolite. For example, species of
the Phyllanthus genus are traditionally used for conditions such
as jaundice, gonorrhea, frequent menstruation, diabetes and as a
pain killer (Naaz et al., 2007; Patel et al., 2011). A study revealed
that Phyllanthus urinaria inhibits CYP2E1 activity in hepatocytes
and it also attenuates acetaminophen induced hepatotoxicity in
mice. The experiment was conducted by treating a total of 37mice
with acetaminophen at a dose of 550mg/kg of body weight on day
one in order to induce liver injury. The mice were then divided
into two groups: the first group was treated with Phyllanthus
Table 4 | Medicinal plant species listed in RENISUS with reported
effects of on CYP2D6.
Plant
species/Family
Effects on CYP2D6 References
Allium sativum
(Aliaceae)
NE Markowitz et al.,
2003
Eucalyptus globulus
(Myrtaceae)
− Unger and Frank,
2004
Harpagophytum
procumbens
(Pedaliaceae)
NE, − Modarai et al., 2011
Mentha piperita
(Lamiaceae)
− Unger and Frank,
2004
Phyllanthus amarus
(Euphorbiaceae)
− Hari Kumar and
Kuttan, 2006
Punica granatum
(Lythraceae)
− Usia et al., 2006
Trifolium pratense
(Fabaceae)
− Unger and Frank,
2004
+, Enzyme induction; −, Enzyme inhibition; NE, No Effect.
Table 5 | Medicinal plant species listed in RENISUS with reported
effects of on CYP2E1.
Plant
species/Family
Effects on CYP2E1 References
Allium sativum
(Aliaceae)
− Le Bon et al., 2003
Curcuma longa
(Zingiberaceae)
NE Salama et al., 2013
Glycine max
(Leguminosae)
NE Shon and Nam,
2004
Momordica charantia
(Cucurbitaceae)
Raza et al., 1996
Phyllanthus amarus
(Euphorbiaceae)
Hari Kumar and
Kuttan, 2006
Phyllanthus urinaria
(Euphorbiaceae)
Shen et al., 2008
Punica granatum
(Lythraceae)
Faria et al., 2007a
+, Enzyme induction; Enzyme inhibition; NE, No Effect.
urinaria extract from day 2 to 4 whereas the second group just
received water. The final results indicated that the herbal drug
was able to inhibit the formation of NAPQI and, consequently,
prevent liver failure (Hau et al., 2009).
CYP3A
The most abundant subfamily of cytochromes is CYP3A (it rep-
resents about 30% of the entire CYP450 enzymes in the liver)
and it is responsible for processing more than 50% of thera-
peutic drugs. CYP3A exists in the body in three isoforms: 3A4,
3A5, and 3A7. CYP3A5 is more often detected in adolescents
than in adults, where it is hardly inducible. CYP3A4 is mostly
glucocorticoid-inducible and CYP3A7 (found only in fetal liv-
ers) has a role in hydroxylations of allylic and benzylic carbon
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atoms (Ionescu and Caira, 2005). According to our findings,
practically all the medicinal plants that demonstrated activ-
ity in the Phase 1 metabolism are substrates for the CYP3A
family (Table 6). Macrolide antibiotics, anti-arrythmics, benzo-
diazepines, immune modulators, HIV antivirals, antihistamines,
calcium channel blockers and HMG CoA reductase inhibitors are
examples of classes of medications metabolized by the CYP3A
subfamily (Zhou et al., 2009). The probability of herb-drug
interactions with this isoform is high and therefore a particu-
lar attention to all CYP3A substrates should be given in order to
avoid herb-drug interactions.
HIV positive patients are commonly treated with the essen-
tial drug Saquinavir. At the same time, dietary supplements such
as garlic and/or immune system boosters like Cat’s claw can be
used to help prevent, combat and improve health. In 1998, a case
report was published demonstrating that Saquinavir is a substrate
of CYP3A4 and that garlic (an inhibitor of CYP3A) was able to
interfere with the metabolism of the drug, leading to failures in
therapy and possible drug resistance (Chen et al., 2011). Another
case report showed that a 45-year-old woman, who was HIV pos-
itive and had cirrhosis caused by a hepatitis C infection was not
responding satisfactorily to the treatment of the anti-HIV drugs.
Table 6 | Medicinal plant species listed in RENISUS with reported
effects of on CYP3A.
Plant
species/Family
Effects on CYP3A References
Allium sativum
(Aliaceae)
NE, −(*/**/***) Foster et al., 2001;
Hajda et al., 2010
Chamomilla recutita
(Asteraceae)
−(*) Budzinski et al.,
2000
Curcuma longa
(Zingiberaceae)
NE(*) Graber-Maier
et al., 2010
Eucalyptus globulus
(Myrtaceae)
−(*) Unger and Frank,
2004
Foeniculum vulgare
(Apiaceae)
−(*) Subehan et al.,
2006, 2007
Harpagophytum
procumbens
(Pedaliaceae)
NE, −(*) Unger and Frank,
2004; Modarai
et al., 2011
Mentha piperita
(Lamiaceae)
−(*) Unger and Frank,
2004
Mormodica charantia
(Cucurbitaceae)
−(*) Raza et al., 1996
Phyllanthus amarus
(Euphorbiaceae)
−(*/**/***) Hari Kumar and
Kuttan, 2006
Punica granatum
(Lythraceae)
−(*/**/***) Faria et al., 2007a
Trifolium pratense
(Fabaceae)
−(*) Budzinski et al.,
2000
Uncaria tomentosa
(Rubiaceae)
−(*) Budzinski et al.,
2000
Zingiber officinale
(Zingiberaceae)
(*) Kimura et al., 2010
*CYP3A4, **CYP3A5, ***CYP3A7/+, Enzyme induction; −, Enzyme inhibition;
NE, No Effect.
The patient had no good adherence to the HIV treatment so was
then asked whether she was making use of any other medicines,
including herbal medicines. Surprisingly, the patient was taking
Uncaria tomentosa preparation for 2months, probably to enhance
the immune system. She was asked to cease taking of the herbal
medicine and after 15 days the Cmin values of the anti-HIV drugs
were normalized. As shown in Table 6, Uncaria tomentosa has a
high inhibitory capability to CYP3A4 causing an increase in the
Cmin values for antiretroviral agents leading to an increased risk
of toxicity. The combined therapy with these two agents has been
shown to be a potential risk for HIV patients (Lopez Galera et al.,
2008).
Another example of a CYP3A substrate is the HMG CoA
reductase inhibitor Atorvastatin. This essential medicine is indi-
cated for patients with dyslipidemia, reducing levels of total
cholesterol, low-density lipoprotein cholesterol (LDL), triglyc-
erides, very low-density lipoprotein cholesterol (VLDL) and for
increasing high-density lipoprotein cholesterol (HDL) levels. A
pharmacokinetic study conducted in 2012 showed that the half-
life of the drug was increased in rats treated with Allium sativum
due to inhibition of CYP3A4 by the herbal medicine (Reddy et al.,
2012).
REFARGEN has reported CYP3A5 polymorphisms among
Brazilians with the most frequent alleles being CYP3A5∗1, ∗3,
∗6, and ∗7. The alleles ∗3 and ∗6 decrease enzyme activity
in vitro, whereas ∗1 and ∗7 showed no effects (Zhou et al., 2009).
Interestingly, the allele ∗3 is the most common variation of this
isoform in Brazil. Because it reduces the enzyme activity, intake
of herbal medicines that exert the same effect should be strongly
avoided in order to prevent herb-drug interactions.
PHASE 2 METABOLISM AND POTENTIAL
PHARMACOKINETIC HERB-DRUG INTERACTIONS
Phase 2 metabolism reactions (or Conjugation reactions) occur
when metabolic enzymes react with functional groups of a drug
that was formed during the Phase 1 process. Endogenous species,
such as a sugar or an amino acid, are added to the drug in order to
increase the polarity to allow its elimination. The two main Phase
2 biotransformation reactions are glutathione conjugation and
glucuronidation but the other conjugative reactions such as sul-
fonation, methylation and acetylation are also relevant (Atkinson,
2012).
GLUTATHIONE CONJUGATION (GSH)
Glutathione is a tripeptide present in high concentrations in the
liver. It has a protective role removing toxic electrophilic com-
pounds from the body (Ionescu and Caira, 2005). Conjugation
with glutathione avoids the reaction of electrophilic compounds
to nucleophilic ones in macromolecules such as proteins and
nucleic acids. When the conjugate is formed, it has to undergo
further metabolic reactions in order to form mercapturic acid.
The final product is then eliminated from the organism (Sies and
Ketterer, 1988).
The plant species on Table 7 can affect the glutathione levels
in liver cells according to our literature search. The metabo-
lite NAPQI, generated by the CYP isoforms 2E1, 3A4, and 1A2,
undergoes glutathione conjugation (Baxter and Stockley, 2008).
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Table 7 | Medicinal plant species listed in RENISUS with reported
effects of on glutathione levels.
Plant species/Family Effects on References
glutathione levels
Achillea millefoilum
(Asteraceae)
+ Potrich et al., 2010
Allium sativum
(Aliaceae)
+ Ip and Lisk, 1997
Aloe vera/Aloe
barbadensis (Aloaceae)
−, + Kaithwas et al.,
2011; Hegazy et al.,
2012
Anacardium
occidentale
(Anacardiaceae)
+ Singh et al., 2004
Baccharis trimera
(Asteraceae)
− Nogueira et al., 2011
Bauhinia forficata
(Caesalpiniaceae)
− Damasceno et al.,
2004
Bauhinia variegata
(Caesalpiniaceae)
+ Rajkapoor et al.,
2006
Calendula officinalis
(Asteraceae)
+ Preethi and Kuttan,
2009
Chamomilla recutita
(Asteraceae)
+ Al-Hashem, 2010
Croton cajucara
(Euphorbiaceae)
+ Rabelo et al., 2010
Curcuma longa
(Zingiberaceae)
+ Rong et al., 2012
Cynara scolymus
(Asteraceae)
+, NE Miccadei et al.,
2008
Foeniculum vulgare
(Apiaceae)
+ Zhang et al., 2012
Glycine max
(Leguminosae)
+ Barbosa et al., 2011
Mentha pulegium
(Lamiaceae)
+ Alpsoy et al., 2011
Mentha piperita
(Lamiaceae)
+ Sharma et al., 2007
Mikania glomerata
(Asteraceae)
NE Barbosa et al., 2012
Momordica charantia
(Cucurbitaceae)
+ Raza et al., 2000,
1996
Phyllanthus amarus
(Euphorbiaceae)
+ Kumar and Kuttan,
2004, 2005; Karuna
et al., 2009; Maity
et al., 2013
Phyllanthus niruri
(Euphorbiaceae)
+ Bhattacharjee and
Sil, 2006; Manjrekar
et al., 2008
Psidium guajava
(Myrtaceae)
+ Tandon et al., 2012
Punica granatum
(Myrtaceae)
+, − Faria et al., 2007b;
Dassprakash et al.,
2012
Ruta graveolens
(Rutaceae)
+ Ratheesh et al.,
2011
Zingiber officinale
(Zingiberaceae)
+, NE Ajith et al., 2007
+, Enzyme induction; − Enzyme inhibition; NE, No Effect.
When production of NAPQI exceeds liver stores of glutathione,
the organ is damaged due to the attachment of NAPQI to liver
proteins (Alipour et al., 2013). Thus, a combined therapy of
acetaminophen and herbal species that deplete glutathione levels,
listed in Table 7, should be monitored.
A study demonstrated that consumption of garlic extract
protects hepatocytes against acetaminophen-induced glutathione
depletion. In order to measure glutathione levels, hepatocytes
were isolated from male Sprague-Dawley rats and incubated
with different concentrations of garlic extract at three different
times: before, at the same time and 30min after addition of
acetaminophen. The results were collected at different time points
(from 0 to 150min) and it was observed that the intake of garlic
extract is able to protect hepatocytes against acetaminophen-
induced toxicity by increasing intracellular GSH levels (Anoush
et al., 2009).
Studies on polymorphisms in the Brazilian population
of enzymes in glutathione conjugation, such as glutathione
S-tranferase (GST) have not been carried out by REFARGEN.
However, some reports revealed its existence among this popu-
lation. A study conducted by Rossini et al. (2002) reported the
existence of GST polymorphisms in a group of 519 Brazilians
from Rio de Janeiro. GSTM1 is involved in the detoxification of
polycyclic aromatic hydrocarbons and some mutagens, whereas
GSTT1 catalyzes the metabolism of halomethanes by human ery-
throcytes. It was found that the null allele, i.e., no expression
of the enzyme, was detected in approximately 10% of the stud-
ied population. Null individuals are generally more susceptible to
DNA damage by the action of the compounds already mentioned.
Although we cannot extrapolate this data for all Brazilians, the
existence of these polymorphisms is thought to be quite common
among multi-ethnic populations. Therefore, the extensive list of
plant species found to affect the glutathione conjugation mecha-
nism plus the presence of such polymorphisms could potentially
increase chances of herb-drug interactions.
GLUCURONIDATION
Glucuronidation is a mechanism in which a glucuronide
is formed by the reaction between the electrophilic C-1
atom of the pyranose acid ring of the co-factor UDPGA
(uridine 5′-diphosphate-glucuronic acid) with the substrate
catalyzed by UDP-glucuronosyltransferases (UGTs). Uridine
diphosphate glucuronosyltransferases (UGT’s) are the most
important Phase 2 enzymes and they are found in the highest
amount among all conjugation enzymes in the liver (Ionescu and
Caira, 2005; Caira and Ionescu, 2006). This is the most important
form of conjugation of xenobiotics with chemical groups such
as alcohols, phenols, hydroxylamines, carboxylic acids, amines,
sulphonamides, and thiols (Gibson and Skett, 2001).
Phase 1 metabolites of nonsteroidal anti-inflammatory drugs
(NSAIDs), such as Ibuprofen, predominantly undergo glu-
curonidation in order to be eliminated from the organism (Kuehl
et al., 2005). Allium sativum increases the expression of UGTs
whereas Curcuma longa inhibits the expression of these enzymes
in the liver (Table 8). Therefore, the pharmacokinetic of this class
of drugs can be compromised by consumption of any of these
herbal species.
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REFARGEN has not yet published data about polymorphisms
on UDP- glucuronosyltransferase enzymes. However, informa-
tion about polymorphic UGTs and its impact on ADRss and
cancer susceptibility have been reported (Guillemette, 2003).
OTHER CONJUGATIVE REACTIONS
Besides the two main liver conjugation reactions (glutathione
conjugation and glucuronidation), the xenobiotic transformation
could also happen by sulfation (or sulfate conjugation), methyla-
tion (or methyl conjugation), and acetylation (Ionescu and Caira,
2005).
Sulfation is another Phase 2 detoxification mechanism that
is recognized to be the major conjugation pathway for phe-
nols, alcohols, amines and thiols (Ionescu and Caira, 2005).
Before the Phase 1 metabolites undergo sulfate conjugation,
the inorganic sulfate has to be activated via ATP to form
adenosine-5′-phosphosulphate (APS) and, consequently, 3′-
phosphoadenosine-5′-phosphosulphate (PAPS). Sulfotransferase
enzymes (SULT) will then catalyze the detoxification of
essential drugs, such as Salbutamol and Acetaminophen by
transferring a sulfuryl group from PAPS to an acceptor
molecule (Gibson and Skett, 2001). Methylation is the mainly
metabolic pathway for endogenous compounds but it could
be also the route of many drugs and xenobiotics in general
(Weinshilboum, 1988). Methyl conjugate reactions are only pos-
sible in the presence of the co-factor S-adenosylmethionine
(SAM) and will result in the formation of O-methylated, N-
methylated, and S-methylated products (Gibson and Skett,
2001). The liver is the primary site for acetylation reactions,
but the reaction could also happen in some extra hepatic
sites, such as the spleen, lungs and gut. To summarize, the
N-acetyltransferases will catalize the transferring of the co-
factor acetyl-coenzyme A (acetyl-CoA) to aromatic amines and
sulphonamides and form the polar metabolites (Ionescu and
Caira, 2005).
After the literature search, it was concluded that the 71 plant
species that are the focus of this review need to have their
pharmacokinetic profile studied, because no such data has been
published. The risk of potential herb-drug interactions caused by
herbal medicines that are metabolized through sulfation, methy-
lation and acetylation pathways is therefore increased and it
could be already affecting the efficacy of conventional drugs.
REFARGEN has not published any data about genetic poly-
morphisms in the Brazilian population for these conjugation
mechanisms to date.
Table 8 | Medicinal plant species listed in RENISUS with reported
effects of on UGT levels.
Plant
species/Family
Effects on UGT levels References
Allium sativum
(Aliaceae)
+ Ip and Lisk, 1997
Curcuma longa
(Zingiberaceae)
− Naganuma et al.,
2006
+, Enzyme induction; −, Enzyme inhibition; NE, No Effect.
EFFECTS OF PLANT SPECIES ON P-GLYCOPROTEIN (Pgp)
ACTIVITY AND HERB-DRUG INTERACTION
Drug-transporter proteins are known to allow xenobiotics to
cross biological membranes, the most well-known one being
Pgp. This protein plays a role as an efflux pump that pushes
metabolites and drugs out of the cells which can result in pharma-
cokinetic alterations (Williamson et al., 2009). Some metabolites
generated by the metabolism of herbal medicines can be pumped
back to the lumen due to the activity of P-glycoprotein and hence,
oral delivery can be compromised (Butterweck et al., 2004).
Among the herbal medicines that are the object of this review,
Achillea millefolium demonstrated inhibition of P-glycoprotein
whereas Allium sativum activates the transporter (Table 9). Herb-
drug interactions have already been reported on Pgp activity.
For example, the HIV-protease inhibitor Saquinavir (substrate of
CYP3A4) is absorbed in the intestine via P-glycoprotein. As gar-
lic extracts may induce Pgp activity, the outcome of concomitant
consumption of the herbal medicine with the essential drug could
potentially reduce the bioavailability of the latter (Williamson
et al., 2009).
Studies have shown that the gene ABCB1, which encodes
Pgp, is very polymorphic and that the pharmacokinetics of sev-
eral Pgp substrates could be significantly altered (Scheiner et al.,
2010). REFARGEN has identified three ABCB1 polymorphisms
in the Brazilian population: 1236T (rs1128503), 2677non G
(rs2032582), and 3435T (rs1045642). Pharmacokinetic studies of
drugs that affect the regulation of ABCB1, will help in the future
in order to avoid herb-drug interactions on that level.
PHARMACOVIGILANCE OF HERBAL MEDICINES
The increasing consumption of herbal medicines in the world
raises a concern about their rational use by the population. The
WHO has recognized the potential risks of uncontrolled use of
herbal medicines in conjunction with other medicines and hence,
this Organization issued in 2004 the “Guidelines on safety moni-
toring of herbal medicines in pharmacovigilance systems.” These
guidelines indicate how member countries should include herbal
medicines to an existent pharmacovigilance system to facilitate
the exchange of information (WHO, 2004). After the estab-
lishment of ANVISA in 1999, efforts were concentrated on the
creation of a national system of pharmacovigilance, and in 2001
the National Center for DrugMonitoring (CNMM) was founded.
Notifications of ADRs in Brazil is currently made through an
Table 9 | Medicinal plant species listed in RENISUS with reported
effects of on P-glycoprotein activity.
Plant
species/Family
Effects on P-glycoprotein activity References
Achillea millefolium
(Asteraceae)
− Haidara et al.,
2006
Allium sativum
(Aliaceae)
+ Hajda et al.,
2010
Curcuma longa
(Zingiberaceae)
NE Graber-Maier
et al., 2010
+, Efflux increased; −, Efflux decreased.
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electronic system called NOTIVISA and these data come from
three different sources: a “Sentinel Network,” which provides
information on adverse reactions related to the use of health
products in hospitals, such as drugs, blood and hemoderivatives;
pharmacies will report suspected cases of drug reactions (includ-
ing herb-drug interactions); and a scheme of “Spontaneous
Notifications” that can be made by any health professional reg-
istered into the electronic system (Mendes et al., 2008).
The number of ADRs notified by pharmacovigilance systems
in the world until 2012 resulting from herb-drug interactions was
811, with Allium sativum,Mentha piperita, Zingiber officinale and
Glycine max among the top 20 of the most commonly reported
herbal medicines. Brazil was not included in the list of countries
which have reported herb-drug interactions, demonstrating the
difficulties in collection of such data by the pharmacovigilance
system (Skalli and Soulaymani Bencheikh, 2012). Since the cre-
ation of NOTIVISA in 2008, there are no notifications of adverse
reactions to herbal medicines, demonstrating that the new system
created more obstacles to the users (Balbino and Dias, 2010).
Most of the problems related to the notification of ADRs due to
herbal medicine consumption occur mainly because Practitioners
and other health professionals are not well trained to detect the
origin of the reaction. Besides, patients in general do not inform
their use of herbal medicines and Physicians may not have suf-
ficient knowledge about the effects of the phytomedicines in the
body. Thus, educational campaigns should be utlilized in order to
emphasize the rational use of medicinal plants and also to encour-
age health professionals to notify any adverse effect that might be
a result of herb-drug interaction (Balbino and Dias, 2010).
CONCLUSIONS
In 2008 Brazil became a model country, clearly defining a positive
list of herbal medicines considered “essential,” and implement-
ing an agenda to make possible the complete implementation of
herbal medicines at a clinical level in the foreseeable future. This
is a leading example within the current global trend toward the
integration of herbal medicines into the healthcare system.
Our review highlights that little is known about native
Brazilian plants. Most of the data is related to herbal medicines
used worldwide, such as garlic, mint and devil’s claw. We tried
to interpret this in the context of the genetic makeup of the
Brazilian population and how this may interact with essential
drugs prescribed within the Brazilian healthcare system. It is evi-
dent that an enormous task should be undertaken to understand
the pharmacokinetics of most local plant species.
Ensuring safety of herbal medicines goes beyond the interpre-
tation of the preclinical or clinical evidence. Quality is also on
the basis of safety and this is a challenging task in the field of
Phytotherapy, with many drugs lacking identifiable active prin-
ciples. Healthcare professionals and the public alike have to be
well trained/informed in the use of the final medicinal product.
Moreover, only a robust system of pharmacovigilance will help in
the identification of relevant safety issues at a population level.
These are not necessarily mirroring the preclinical and clinical
data available.
At this stage, the preclinical pharmacokinetic profile of medic-
inal plants can only be evaluated with available data in literature.
Polymorphism studies in the Brazilian population have been a
valuable source of information that can help with the assessment
of ADRs and herb-drug interactions.
By tentatively exploring any potential interaction between
herbal medicines and other essential medicines in the Brazilian
system, we hope to open up future research to both bridge the
gaps in knowledge and support future risk assessment of herb-
drug combinations. Again, our results highlight that much more
work is needed as over half of the medicinal plants lack data.
Only after this is done can we start assessing the risk of herb-drug
interactions when medicinal plants are taken with any essential
drug.
Safety of herbal medicines finally lies in the hands of the
patients. In this regard, healthcare professionals need proper
training on how to advise the patient and the labeling of the
product must anticipate further doubts when the patient cannot
communicate with the professional.
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